Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034146 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1PTGS1KMT2AMEN1 | |
| SCHEMBL19531542 | 0.80 | CYP2A6 (0.52) | ALDH1A1L3MBTL1KMT2AMEN1KDM4E | |
| SCHEMBL3538039 | 0.80 | HSD17B10 (0.52) | ALDH1A1KMT2AMEN1KDM4ENPC1 | |
| SCHEMBL3542039 | 0.79 | KIF11 (0.42) | ALDH1A1L3MBTL1NPC1LMNARAB9A | |
| SCHEMBL913164 | 0.79 | NPC1 (0.58) | ALDH1A1KMT2AMEN1KDM4ENPC1 | |
| SCHEMBL4425760 | 0.77 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1PTGS1KMT2AMEN1 | |
| SCHEMBL28325163 | 0.76 | NPC1 (0.54) | ALDH1A1KMT2AMEN1KDM4ENPC1 | |
| SCHEMBL3608546 | 0.75 | P4HTM (0.49) | ALDH1A1KMT2AMEN1KDM4ENPC1 | |
| SCHEMBL508261 | 0.75 | KCNH2 (0.42) | ALDH1A1L3MBTL1KCNH2 | |
| SCHEMBL3608544 | 0.75 | P4HTM (0.49) | ALDH1A1KMT2AMEN1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
| US-4774020-A | LIQUID CRYSTAL DISPLAYS | CHISSO CORPORATION (JP) | 1988-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | ALDH1A1 2657/4885L3MBTL1 3440/4885PTGS1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.